chr16-88643560-A-G
Variant names:
Variant summary
Our verdict is Benign. Variant got -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BS1BS2
The NM_000101.4(CYBA):c.381T>C(p.Arg127Arg) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0325 in 1,532,918 control chromosomes in the GnomAD database, including 1,029 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).
Frequency
Genomes: 𝑓 0.025 ( 74 hom., cov: 33)
Exomes 𝑓: 0.033 ( 955 hom. )
Consequence
CYBA
NM_000101.4 synonymous
NM_000101.4 synonymous
Scores
1
6
Clinical Significance
Conservation
PhyloP100: -4.72
Genes affected
CYBA (HGNC:2577): (cytochrome b-245 alpha chain) Cytochrome b is comprised of a light chain (alpha) and a heavy chain (beta). This gene encodes the light, alpha subunit which has been proposed as a primary component of the microbicidal oxidase system of phagocytes. Mutations in this gene are associated with autosomal recessive chronic granulomatous disease (CGD), that is characterized by the failure of activated phagocytes to generate superoxide, which is important for the microbicidal activity of these cells. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -21 ACMG points.
BP4
Computational evidence support a benign effect (MetaRNN=0.0066922307).
BP6
Variant 16-88643560-A-G is Benign according to our data. Variant chr16-88643560-A-G is described in ClinVar as [Benign]. Clinvar id is 255127.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr16-88643560-A-G is described in Lovd as [Benign].
BP7
Synonymous conserved (PhyloP=-4.72 with no splicing effect.
BS1
Variant frequency is greater than expected in population nfe. gnomad4 allele frequency = 0.0248 (3771/151950) while in subpopulation NFE AF= 0.0385 (2618/67916). AF 95% confidence interval is 0.0373. There are 74 homozygotes in gnomad4. There are 1810 alleles in male gnomad4 subpopulation. Median coverage is 33. This position pass quality control queck.
BS2
High Homozygotes in GnomAd4 at 74 AR gene
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0248 AC: 3771AN: 151844Hom.: 74 Cov.: 33
GnomAD3 genomes
AF:
AC:
3771
AN:
151844
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0209 AC: 2715AN: 130142Hom.: 56 AF XY: 0.0197 AC XY: 1405AN XY: 71382
GnomAD3 exomes
AF:
AC:
2715
AN:
130142
Hom.:
AF XY:
AC XY:
1405
AN XY:
71382
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0333 AC: 46053AN: 1380968Hom.: 955 Cov.: 37 AF XY: 0.0321 AC XY: 21906AN XY: 681722
GnomAD4 exome
AF:
AC:
46053
AN:
1380968
Hom.:
Cov.:
37
AF XY:
AC XY:
21906
AN XY:
681722
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0248 AC: 3771AN: 151950Hom.: 74 Cov.: 33 AF XY: 0.0244 AC XY: 1810AN XY: 74280
GnomAD4 genome
AF:
AC:
3771
AN:
151950
Hom.:
Cov.:
33
AF XY:
AC XY:
1810
AN XY:
74280
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
111
ALSPAC
AF:
AC:
143
ESP6500AA
AF:
AC:
8
ESP6500EA
AF:
AC:
147
ExAC
AF:
AC:
542
Asia WGS
AF:
AC:
5
AN:
3462
ClinVar
Significance: Benign
Submissions summary: Benign:6
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not specified Benign:2
-
PreventionGenetics, part of Exact Sciences
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing
- -
Sep 25, 2015
Eurofins Ntd Llc (ga)
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing
- -
not provided Benign:2
-
Breakthrough Genomics, Breakthrough Genomics
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: not provided
- -
Mar 03, 2015
GeneDx
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing
- -
Chronic granulomatous disease Benign:1
Sep 16, 2020
Natera, Inc.
Significance: Benign
Review Status: no assertion criteria provided
Collection Method: clinical testing
- -
Granulomatous disease, chronic, autosomal recessive, cytochrome b-negative Benign:1
Feb 03, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing
- -
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
FATHMM_MKL
Benign
N
MetaRNN
Benign
T
PROVEAN
Pathogenic
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at